Bixiang Zhang

机构：Tongji Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-1609-7260

发表论文 281 篇 · 总被引 14462 次 · h-index 61

代表论文

• Cancer stem cells and niches: challenges in immunotherapy resistance (2025 · Molecular Cancer · 被引 86)
• Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment (2025 · Molecular Cancer · 被引 52)
• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer (2024 · Clinical and Molecular Hepatology · 被引 42)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression (2025 · Gut · 被引 27)